Innate Pharma S.A (IPH) | Stock Overview & Key Data
Innate Pharma S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €17.85 on April 20, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108.28M Small-cap | 0.00% | 23.20% | 42.59% | 42.59% | 42.59% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | |
|
Abivax SA
ABVX
|
7.61B Large-cap | -36.61% | -28.82% | -25.31% | -26.24% | -38.04% | 2,047.73% | 517.65% | 305.72% | 1,019.45% | 447.83% | 447.83% |
|
Nanobiotix
NANO
|
1.39B Large-cap | -12.69% | 13.65% | 14.38% | 69.14% | 58.63% | 827.52% | 612.13% | 134.60% | 81.06% | 449.03% | 449.03% |
|
Abionyx Pharma S.A
ABNX
|
128.36M Small-cap | -8.55% | -18.48% | -12.03% | -26.26% | -28.90% | 120.00% | 121.71% | 123.44% | -65.29% | -76.80% | -76.80% |
|
Maat Pharma S.A.C.A
MAAT
|
99.87M Small-cap | 4.27% | -50.17% | -51.97% | -51.97% | -51.97% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% |
|
Adocia S.A
ADOC
|
90.92M Small-cap | -16.80% | -12.18% | -33.92% | -48.11% | -38.93% | 33.97% | 24.49% | -48.16% | -91.56% | -47.55% | -47.55% |
Ownership & Short Interest
Calculate Your Innate Pharma S.A Investment Returns
Long-Term Investment Performance Analysis
Innate Pharma S.A stock price in Mar 2026 was €1.10, A €1,000.00 lump sum investment in Innate Pharma S.A made 0 years ago would be worth approximately €1,400.00 today, representing a positive return of 40.00%.
2 Months Investment Scenario (Mar 2026 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is IPH's 52-week high and low?
- In the last 52 weeks, Innate Pharma S.A reached a high of €2.20 (on May 15, 2026) and a low of €1.03 (on March 23, 2026).
- What is the market cap and P/E ratio for IPH?
- Curious about Innate Pharma S.A's size and valuation? Its market capitalization stands at 108.28M. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.05, and the forward P/E (looking ahead) is 0.55.
- Does IPH pay dividends? If so, what's the yield?
- As for dividends, Innate Pharma S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Innate Pharma S.A's main competitors or similar companies to consider before investing?
When looking at Innate Pharma S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 2,047.73% 517.65% Nanobiotix
NANO1.39B Healthcare Biotechnology 827.52% 612.13% Abionyx Pharma S.A
ABNX128.36M Healthcare Biotechnology 120.00% 121.71% Maat Pharma S.A.C.A
MAAT99.87M Healthcare Biotechnology -56.15% -56.15% Adocia S.A
ADOC90.92M Healthcare Biotechnology 33.97% 24.49% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Innate Pharma S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Innate Pharma S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 226.58%, the Debt to Equity ratio from the most recent quarter is -1.04, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for IPH?
- Looking at Innate Pharma S.A's growth, its revenue over the trailing twelve months (TTM) was €9M. Compared to the same quarter last year (YoY), quarterly revenue grew by -46.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of IPH stock is held by insiders and institutions?
- Wondering who owns Innate Pharma S.A stock? Company insiders (like executives and directors) hold about 25.70% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 8.23%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.